A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Inclusion Criteria: * Chinese male or female participants, greater than or equal to (≥) 18 years of age * Histologically confirmed metastatic melanoma (surgically unresectable Stage IIIC or Stage IV, American Joint Committee on Cancer) * Treatment-naïve or having received prior systemic treatments for metastatic melanoma * Positive BRAF V600 mutation result determined by a designated laboratory using the Cobas 4800 BRAF V600 Mutation Test * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Previous allowed chemotherapy, immunotherapy, or radiation therapy must have been completed at least 2 weeks prior to study drug administration, and all associated toxicity must be resolved (to less than or equal to \[≤\] Grade 1 or baseline) * Recovery from effects of any major surgery (excluding tumor biopsy at baseline) or significant traumatic injury at least 14 days before the first dose of study treatment * Adequate hematologic, renal, and liver function as defined by protocol * Fertile men and women must use an effective method of contraception during treatment and for ≥6 months after completion of treatment as directed by their physician (in accordance with local requirements). * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy greater than (\>) 3 months * Able to swallow pills Exclusion Criteria: * Active central nervous system (CNS) lesions (radiographically unstable/symptomatic lesions), except participan…